[{"indications": "Indications\u00a0see under Dose below", "name": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA"], "cautions": "Cautions\u00a0see Epoetin", "side-effects": "Side-effects\u00a0see Epoetin; also hot flushes reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200088.htm", "doses": ["Symptomatic anaemia associated with chronic kidney disease\r\nin patients on dialysis and not currently treated\r\nwith erythropoietins (see also MHRA/CHM advice), adult over 18 years, by subcutaneous or intravenous injection, initially\r\n600\u00a0nanograms/kg once every 2 weeks, adjusted according to response\r\nat intervals of at least 4 weeks; maintenance dose of double the previous\r\nfortnightly dose may be given every 4 weeks", "Symptomatic anaemia associated with chronic kidney disease in\r\npatients not on dialysis and not currently treated with erythropoietins (see also MHRA/CHM advice), adult over 18 years, by subcutaneous injection, initially 1.2\u00a0micrograms/kg once every 4 weeks, alternatively by subcutaneous or intravenous\r\ninjection, initially 600\u00a0nanograms/kg once every 2 weeks;\r\ndose adjusted according to response at intervals of at least 4 weeks;\r\npatients treated once every 2 weeks may be given a maintenance dose\r\nof double the previous fortnightly dose every 4 weeks", "Symptomatic anaemia associated with chronic kidney disease in\r\npatients currently treated with erythropoietins (see also MHRA/CHM advice), adult over 18 years, by subcutaneous or intravenous injection, consult\r\nproduct literature", "Subcutaneous route preferred in patients\r\nnot on haemodialysis. Reduce dose by approximately 25% if rise in\r\nhaemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks, or if haemoglobin\r\nconcentration approaches or exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous dose"], "pregnancy": "Pregnancy\u00a0no evidence of harm in animal studies\u2014manufacturer\r\nadvises caution"}]